Randomized trial or adjuvant tamoxifen pour years vs two years in node positive breast cancer women.

被引：0

作者：

Gallén, M ^{[1
]}

Alonso, C ^{[1
]}

Ojeda, B ^{[1
]}

Viladíu, P ^{[1
]}

Beltrán, W ^{[1
]}

Borrás, J ^{[1
]}

Tusquets, I ^{[1
]}

Arcusa, A ^{[1
]}

Barnadas, A ^{[1
]}

Bastús, R ^{[1
]}

Balil, A ^{[1
]}

Batiste-Alentorn, E ^{[1
]}

Guasch, I ^{[1
]}

Garau, I ^{[1
]}

Boleda, W ^{[1
]}

Badia, A ^{[1
]}

机构：

[1] Hosp Del Mar, Barcelona, Spain

来源：

EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S56 / S56

页数：1

共 50 条

[41] aTTom (adjuvant Tamoxifen-To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer-Preliminary results
Gray, R. G.
Rea, D. W.
Handley, K.
Marshall, A.
Pritchard, M. G.
Perry, P.
Earl, H. M.
Poole, C. J.
Salman, A.
Lee, M.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[42] Two years of adjuvant tamoxifen in premenopausal patients with breast cancer:: a randomised, controlled trial with long-term follow-up
Rydén, L
Jönsson, PE
Chebil, G
Dufmats, M
Fernö, M
Jirström, K
Källström, AC
Landberg, G
Stål, O
Thorstenson, S
Nordenskjöld, B
EUROPEAN JOURNAL OF CANCER, 2005, 41 (02) : 256 - 264
[43] Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer - A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone and tamoxifen plus fluoxymesterone in women above 65 years of age
Rose, C
Kamby, C
Mouridsen, HT
Andersson, M
Bastholt, L
Moller, KA
Andersen, J
Munkholm, P
Dombernowsky, P
Christensen, IJ
BREAST CANCER RESEARCH AND TREATMENT, 2000, 61 (02) : 103 - 110
[44] CONTROLLED TRIAL OF TAMOXIFEN AS SINGLE ADJUVANT AGENT IN MANAGEMENT OF EARLY BREAST-CANCER - ANALYSIS AT 6 YEARS
BAUM, M
LANCET, 1985, 1 (8433) : 836 - 840
[45] Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer
Rea, D. W.
Gray, R. G.
Bowden, S. J.
Handley, K.
Earl, H. M.
Poole, C. J.
Bates, T.
Dewar, J. A.
Raytor, Z.
Lee, M.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S402 - S402
[46] Comparative results of two adjuvant trials comparing 5 years of an aromatase inhibitor (AI) with 5 years of tamoxifen (TAM) in postmenopausal women with early breast cancer (EBC).
Vakaet, L. A.
Buyse, M.
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S108 - S109
[47] BONE-MINERAL DENSITY IN WOMEN WITH BREAST-CANCER TREATED WITH ADJUVANT TAMOXIFEN FOR AT LEAST 2 YEARS
LOVE, RR
MAZESS, RB
TORMEY, DC
BARDEN, HS
NEWCOMB, PA
JORDAN, VC
BREAST CANCER RESEARCH AND TREATMENT, 1988, 12 (03) : 297 - 301
[48] Adjuvant systemic therapy for women with node-positive breast cancer
O'Reilly, SE
Allan, SJ
Shenkier, TN
Gelmon, KA
Levine, MN
Olivotto, IA
Fields, ALA
Bowman, DM
Bouchard, F
McGregor, M
Jolivet, J
Pritchard, KI
Verma, S
Arjane, GA
Ayoub, J
Champion, PE
Davis, ML
Hicks, S
Hiller, J
Hiscock, J
Liem, SK
Mohamed, MF
Tomiak, EM
Warner, E
CANADIAN MEDICAL ASSOCIATION JOURNAL, 1998, 158 : S52 - S64
[49] GUYS MANCHESTER CMF TRIAL IN NODE POSITIVE BREAST-CANCER - AN UPDATE AT 8 YEARS
OREILLY, SM
RICHARDS, MA
HOWELL, A
RUBENS, RD
BRITISH JOURNAL OF CANCER, 1990, 62 (03) : 522 - 522
[50] A RANDOMIZED TRIAL OF ADJUVANT AMINOGLUTETHIMIDE VERSUS PLACEBO IN POSTMENOPAUSAL PATIENTS WITH NODE POSITIVE BREAST-CANCER
JONES, AL
POWLES, TJ
COOMBES, RC
SMITH, IE
EASTON, D
BRITISH JOURNAL OF CANCER, 1990, 62 (03) : 521 - 522

← 1 2 3 4 5 →